Navigation Links
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines for sale in Canada
Date:2/26/2009

VANCOUVER, Feb. 26 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM) and Nylon product lines in Canada.

"With the approval of the PDO, MONODERM(TM) and Nylon product lines in Canada, we can further extend the global reach of this next-generation suture product beyond the U.S. and Europe," said Dr. William Hunter, President and CEO of Angiotech.

Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures while Quill(TM) SRS MONODERM(TM) is made from a rapidly resorbing polymer and intended primarily for superficial wound closure applications and soft tissue approximation where use of an absorbable suture is appropriate. The monofilament Quill(TM) SRS Nylon is a polyamide suture indicated for use in soft tissue approximation excluding closure of the epidermis.

Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines have both been previously approved for sale in the U.S. and Europe.

About the Quill(TM) Self-Retaining System (SRS)

Quill(TM) SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill(TM) SRS distribute tension across the wound and eliminate the need for knots.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the fourth quarter of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

Quill(TM) is a trademark of Quill Medical, Inc., and MONODERM(TM) is a trademark of Surgical Specialties Corporation, both of which are wholly-owned subsidiaries of Angiotech Pharmaceuticals, Inc.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
2. Angiotech To Participate In The American Academy Of Ophthalmology (AAO) 2007 Annual Meeting
3. Angiotech to participate in CIBC 18th Annual Healthcare Conference
4. Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
5. Boston University School of Medicine receives grant
6. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
7. Pharmacyclics Receives Nasdaq Notification
8. ING Run For Something Better Receives Healthy Youth for a Healthy Future Champion Award
9. International Partnership for Microbicides Receives US $130 Million from UK Government and the Gates Foundation
10. Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... Feb. 4, 2016  Montoya Love is recognized by ... field of Pharmaceuticals. Montoya is the Regulatory Systems Operations ... Manufacturing and selling a ... Dickinson provides healthcare institutions, clinical laboratories and life ... countries across the globe. ...
(Date:2/4/2016)... (NASDAQ: OMCL ), a leading provider of medication ... results for its fiscal year and fourth quarter ended ... GAAP results: Revenue for the fourth quarter of ... from the third quarter of 2015, and up $8.8 ... Revenue for the year ended December 31, 2015 was $484.6 ...
Breaking Medicine Technology: